NICE published draft guidance on tofersen (Qalsody, Biogen) for amyotrophic lateral sclerosis (ALS) caused by SOD1 gene mutations on 19 November 2026, and the consultation runs until 10 December 2026. According to the MND Association, the initial recommendation is not to approve it. The draft is the latest step in an appraisal that started in 2021 and has already changed programme once. For anyone planning a submission in a small, genetically defined population, the route matters as much as the draft.
From technology appraisal to HST
NICE's project page records a long appraisal history. On 11 November 2021 NICE suspended a scoping exercise it had started in error. After a company challenge, the Topic Selection Oversight Panel concluded in August 2023 that the topic should stay in the Technology Appraisal programme.
On 5 September 2024 Biogen told NICE it "will not provide an evidence submission for this appraisal at this time", and the appraisal was suspended. In October 2024 the Prioritisation Board concluded that tofersen met all the criteria for the Highly Specialised Technologies (HST) programme, and the topic was prioritised on 27 November 2024. Biogen later confirmed it would submit to HST in line with NICE's timelines, adding that the decision would have no impact on its early access programme in NHS Trusts.
The draft scope followed in February 2026, the first committee meeting was held on 22 October 2026, and NICE expects to publish final guidance on 17 March 2027.
What the scope asks of the evidence
The draft scope sets out a small population with a severe prognosis. SOD1 mutations cause around 15% of familial and 1% of sporadic ALS, or around 2% of all cases. About 1,500 people are diagnosed with ALS each year in the UK, and more than half die within three years of diagnosis.
The scope sets four terms for the evaluation:
- The comparator is established clinical management. That means best supportive care, including riluzole where appropriate, which NICE appraised in TA20 in 2001.
- Outcomes centre on survival and ventilation. They include overall survival, disease progression, time to permanent ventilation (tracheostomy or more than 22 hours a day of non-invasive ventilation), respiratory and nutritional status, adverse effects and health-related quality of life.
- The model must carry the cost of finding patients. Because use depends on a SOD1 mutation, the economic analysis should include the cost of SOD1 testing in people with ALS who would not otherwise have been tested, with a sensitivity analysis that leaves it out.
- Two questions remain open. The scope asked whether tofersen is a candidate for managed access, and whether it has substantial health-related benefits that the QALY is unlikely to capture.
What the draft does not yet tell us
The four draft guidance documents are listed on the documents page as published on 19 November 2026. We have not read the committee's reasoning, so this article does not report it.
A draft is not the final word. Consultees can comment until 10 December 2026, and the committee can change its view before final guidance, which NICE expects on 17 March 2027.
What it means for market access teams
- Routing is a strategic decision with a long tail. Tofersen spent years between programmes before evaluation began. Teams with an ultra-rare, genetically defined indication should settle the TA or HST question with NICE early and document why.
- Diagnostic costs belong in the base case. NICE asked for the cost of testing patients who would not otherwise be tested. Any targeted therapy where testing is not yet routine should expect the same, and should know how far the result moves when the test cost is removed.
- Plan the evidence for managed access before the first committee. A managed access agreement needs a clear account of what further data would resolve the uncertainty and when it will arrive. For a progressive disease with survival and ventilation outcomes, that plan has to exist before the draft, not after it.
- Keep early access and appraisal separate. Biogen stated that its decision to submit would have no impact on its early access programme. Patients and clinicians judge that continuity, and payers notice when it is unclear.
- Use the consultation. The window closes on 10 December 2026. Benefits outside the QALY need evidence submitted now to count in the final guidance.
To discuss evidence and routing for a rare or ultra-rare indication at NICE, see our work on rare and orphan sectors or get in touch.